Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

Published:2016-04 Issue:4 Volume:17 Page:425-439
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Cristofanilli Massimo,Turner Nicholas C,Bondarenko Igor,Ro Jungsil,Im Seock-Ah,Masuda Norikazu,Colleoni Marco,DeMichele Angela,Loi Sherene,Verma Sunil,Iwata Hiroji,Harbeck Nadia,Zhang Ke,Theall Kathy Puyana,Jiang Yuqiu,Bartlett Cynthia Huang,Koehler Maria,Slamon Dennis

Funder

Pfizer

AstraZeneca

Chugai

Eli Lilly

GSK

Daiichi-Sankyo

Novartis

US Department of Defense Breast Cancer Innovator Award

Revlon/University of California, Los Angeles Women's Cancer Research Program

Peter and Denise Wittich Breast Cancer Program

Publisher

Elsevier BV

Subject

Oncology

Reference32 articles.

1. Growth factor signalling in endocrine and anti-growth factor resistant breast cancer;Nicholson;Rev Endocr Metab Disord,2007

2. Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group study;Elledge;Int J Cancer,2000

3. Relationship between estrogen receptor, progesterone receptor, HER-2 and Ki67 expression and efficacy of aromatase inhibitors in advanced breast cancer;Anderson;Ann Oncol,2011

4. Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer;Sanchez;Breast Cancer Res,2011

5. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer;Toy;Nat Genet,2013

Cited by 1393 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Abemaciclib increases the risk of venous thromboembolism in breast cancer: Integrate meta-analysis, pharmacovigilance database analysis, and in vitro validation;Cancer Treatment Reviews;2024-11

2. Patterns and outcomes in HR+/HER2- advanced/metastatic breast cancer patients in Brazil receiving palbociclib;Future Oncology;2024-09-05

3. The choice of optimal therapy for ER+ HER2-metastatic breast cancer (PROMETHEUS): all-Russian analysis of physicians’ preferences – updated survey results;Medical alphabet;2024-09-05

4. Circulating Tumor DNA and Survival in Metastatic Breast Cancer;JAMA Network Open;2024-09-05

5. Mechanisms of sensitivity and resistance to CDK4/CDK6 inhibitors in hormone receptor-positive breast cancer treatment;Drug Resistance Updates;2024-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3